Images acquired by Assistant Professor Yongjian Liu have been chosen for this year’s NCI Cancer Close-up project. They illustrate PET/CT imaging showing the tumor accumulation of DAPTA peptide functionalized, 64Cu doped gold nanocluster (64Cu-AuNCs-DAPTA) imaging CCR5 receptor in a triple negative breast cancer patient derived xenograph mouse model. The PET image was acquired at 24 h post intravenous injection.
Images acquired by Kvar Black in Prof. Sam Achilefu’s ORL group have been chosen for this year’s NCI Cancer Close-up project. They illustrate multimodal targeted imaging of prostate cancer with F-18-fluorodeoxyglucose and TiO2-based nanophotosensitizer agents, which together show additional promise in depth-independent photodynamic therapy applications.
Dr. Achilefu would like to announce the formation of a 2017 CMMN Pedal the Cause team in support of the Cancer Frontier Fund. This research fund was established in 2009 by Alvin J. Siteman, an emeritus Washington University trustee, chairman of Site Oil Company and president of Flash Oil Company. Since the fund’s inception, 134 awards for a total of $21.7 million have been granted to Washington University faculty focused on cancer research.
100% of Pedal the Cause proceeds stay in St. Louis and go directly to the Cancer Frontier Fund, which supports cancer research at Washington University (WU) and St. Louis Children’s Hospital. Awards granted to WU faculty are managed by Siteman Cancer Center (SCC), a major contributor to CMMN. Participation by CMMN members shows our appreciation to SCC and demonstrates our commitment to both CMMN research and the community effort that raises local cancer research funds.
Team members may participate as riders, spinners or “virtual” riders (simply contribute to the cause). As a participant at the minimum levels, per the Request for Applications, qualifying faculty members may apply for cancer research funding (through the Siteman Investment Program) in one or both of two cycles in the year you participate. Faculty, students, staff and families are more than welcome to join the team.
Registration opens in March of 2017. More details to come. Information on the 2016 event can be found here: https://stlouis.pedalthecause.org/how_it_works.jsp
Please reply and indicate your interest in participating as a rider or virtual rider, as we build our team and ready ourselves for a productive year in 2017!
Agency: Department of Health and Human Services, NIH, NCI
Mechanism: Innovative Research in Cancer Nanotechnology (IRCN) (U01)
FOA Number: PAR-14-285
Grant Term and Amount: 5 years, $450,000 in direct costs per year
Letter of Intent: Not applicable
Application deadline: October 15, 2016
This Funding Opportunity Announcement (FOA) invites applications for the development of innovative research projects in cancer nanotechnology. This initiative, to be known as Innovative Research in Cancer Nanotechnology (IRCN), is an integral component of a broader program – the NCI Alliance for Nanotechnology in Cancer (The Alliance) (https://nano.cancer.gov). IRCN awards are designed to enable multi-disciplinary research and transformative discoveries in cancer biology and/or oncology through the use of nanotechnology. Proposed projects should address major barriers in cancer biology and/or oncology using nanotechnology and should emphasize fundamental understanding of nanomaterial interactions with biological systems and/or mechanisms of their in vivo delivery.
NCI will hold a pre-application informational webinar for this FOA. Date, time, and other details will be posted at https://nano.cancer.gov.